FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 330:574-575 February 24, 1994 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by The International Non-Hodgkin's Lymphoma Prognostic Factors Project

To the Editor: The model of Shipp et al. for predicting survival in patients with aggressive non-Hodgkin's lymphoma (Sept. 30 issue)¹ may represent an improvement over staging alone, but the approximations that the authors use in simplifying their model may limit its value in comparing different groups of treated patients or in assigning risk to an individual patient. The generalizability of their results is limited by several factors.

First, the authors treat the relative risks of the five independent variables as equal, whereas the true values vary by as much as 14 percent from the mean.

Second, in the model . . . [Full Text of this Article]

References

This article has been cited by other articles:

• De Paepe, P., Achten, R., Verhoef, G., Wlodarska, I., Stul, M., Vanhentenrijk, V., Praet, M., De Wolf-Peeters, C. (2005). Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas. JCO 23: 7060-7068 [Abstract] [Full Text]